The distribution and manufacturing of insulin are carried out by very few multinational companies outside the recognized biosimilar manufactures, and a handful of small companies are developing insulin manufacturing abilities built upon up-to-date biotechnological methods, in turn, enhancing the growth and increasing the size of the insulin market. Biosimilars are estimated to cost 20-30% less than their originator drug. Therefore, they offer lower cost alternatives, with the potential to expand market competition and increase access to treatment. A recent report estimated that healthcare systems in the European Union (EU) could save up to USD 110 billion by using biosimilars. The ever rising number of producers who are developing biosimilar insulin may help deliver clinical aid, as compared to the ones currently available for insulin analogs, at a very affordable price.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPANY PROFILES

7. COMPANY SHARE ANALYSIS